Starting on:
Mar 30, 2021
Ending on:
Mar 30, 2021
Moderator(s):
Venue:
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
Mar 30, 2021
Ending on:
Mar 30, 2021
Moderator(s):
THE KAREN HOSPITAL
Max Credits:
3 Points
Provider:
Karen Hospital
Claim Points
JOURNAL CLUB - 30/03/2021
Starting on:
Mar 30, 2021 8:00 AM
Mar 30, 2021 8:00 AM
Ending on:
Mar 30, 2021 9:00 AM
Mar 30, 2021 9:00 AM
Venue:
THE KAREN HOSPITAL
THE KAREN HOSPITAL
Description
Liraglutide is a glucagon-like peptide 1 receptor agonist (GLP-1 RA) approved for the management of hyperglycemia in type 2 diabetes and for reduction of cardiovascular (CV) risk in patients with type 2 diabetes and clinical CV disease (CVD). It is also approved at a higher dose for the treatment of obesity.
Objectives
The Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER) trial (ClinicalTrials.gov reg. no. NCT01179048) demonstrated a reduced risk of cardiovascular (CV) events for patients with type 2 diabetes who received the glucagon-like peptide 1 receptor agonist liraglutide versus placebo. The mechanisms behind this CV benefit remain unclear. We aimed to identify potential mediators for the CV benefit observed with liraglutide in the LEADER trial.
Presenters
-
Dr.
Jane Wavinya
MEDICAL OFFICER
THE KAREN HOSPITAL